{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Oxaliplatin+%28Eloxatin%C2%AE%29", "query": { "intervention": "Oxaliplatin (Eloxatin®)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 79, "total_pages": 8, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Oxaliplatin+%28Eloxatin%C2%AE%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-02T05:57:50.521Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02953509", "title": "Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non Hodgkin Lymphoma" ], "interventions": [ { "name": "Magrolimab", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Allopurinol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 178, "start_date": "2016-11-21", "completion_date": "2024-03-25", "has_results": true, "last_update_posted_date": "2025-05-29", "last_synced_at": "2026-10-02T05:57:50.521Z", "location_count": 16, "location_summary": "Birmingham, Alabama • Duarte, California • Stanford, California + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02953509" }, { "nct_id": "NCT01626664", "title": "KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adult T-cell Leukemia-Lymphoma" ], "interventions": [ { "name": "KW-0761", "type": "BIOLOGICAL" }, { "name": "Pralatrexate", "type": "DRUG" }, { "name": "gemcitabine plus oxaliplatin", "type": "DRUG" }, { "name": "DHAP", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Kyowa Kirin, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 71, "start_date": "2012-06", "completion_date": "2018-02", "has_results": true, "last_update_posted_date": "2024-04-25", "last_synced_at": "2026-10-02T05:57:50.521Z", "location_count": 10, "location_summary": "Los Angeles, California • Miami, Florida • Chicago, Illinois + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01626664" }, { "nct_id": "NCT00859469", "title": "Eloxatin® Plus Gemcitabine Chemotherapy for Mesothelioma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Mesothelioma" ], "interventions": [ { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2004-04", "completion_date": "2013-03", "has_results": true, "last_update_posted_date": "2019-10-30", "last_synced_at": "2026-10-02T05:57:50.521Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00859469" }, { "nct_id": "NCT00502567", "title": "A Study to Assess Safety, Tolerability and PK of AZD2171 and Chemotherapy on Patients With Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor" ], "interventions": [ { "name": "AZD2171", "type": "DRUG" }, { "name": "FOLFOX", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Irinotecan (administered with & without Cetuximab)", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 104, "start_date": "2005-01", "completion_date": "2011-06", "has_results": false, "last_update_posted_date": "2011-07-27", "last_synced_at": "2026-10-02T05:57:50.521Z", "location_count": 3, "location_summary": "Ann Arbor, Michigan • Detroit, Michigan • Nashville, Tennessee", "locations": [ { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00502567" }, { "nct_id": "NCT00061815", "title": "Study of Cetuximab, Oxaliplatin, 5-FU/LV Versus Oxaliplatin, 5-FU/LV in Patients With Previously Treated Metastatic, EGFR-Positive Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "cetuximab", "type": "BIOLOGICAL" }, { "name": "oxaliplatin", "type": "DRUG" }, { "name": "leucovorin", "type": "DRUG" }, { "name": "5-fluorouracil", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 102, "start_date": "2003-03", "completion_date": "2005-11", "has_results": false, "last_update_posted_date": "2010-04-12", "last_synced_at": "2026-10-02T05:57:50.521Z", "location_count": 39, "location_summary": "Little Rock, Arkansas • Springdale, Arkansas • Fountain Valley, California + 36 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Gilroy", "state": "California" }, { "city": "Greenbrae", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00061815" }, { "nct_id": "NCT03615326", "title": "Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Gastric Neoplasms", "Gastroesophageal Junction Adenocarcinoma" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "5-FU", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "S-1", "type": "DRUG" }, { "name": "Trastuzumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 738, "start_date": "2018-10-05", "completion_date": "2025-11-12", "has_results": true, "last_update_posted_date": "2026-08-26", "last_synced_at": "2026-10-02T05:57:50.521Z", "location_count": 23, "location_summary": "Los Angeles, California • Monterey, California • Orange, California + 19 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Monterey", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Newnan", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03615326" }, { "nct_id": "NCT00127036", "title": "Trial for Microarray Analysis of Colon Cancer Outcome-A (MACCO-A)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adenocarcinoma", "Colon Cancer" ], "interventions": [ { "name": "XELOX", "type": "DRUG" }, { "name": "XELIRI", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 65, "start_date": "2003-10", "completion_date": "2010-12", "has_results": true, "last_update_posted_date": "2017-03-23", "last_synced_at": "2026-10-02T05:57:50.521Z", "location_count": 12, "location_summary": "Deerfield Beach, Florida • Fort Lauderdale, Florida • Fort Myers, Florida + 8 more", "locations": [ { "city": "Deerfield Beach", "state": "Florida" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Lakeland", "state": "Florida" }, { "city": "Port Charlotte", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00127036" }, { "nct_id": "NCT04185883", "title": "Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors", "Kirsten Rat Sarcoma (KRAS) pG12C Mutation" ], "interventions": [ { "name": "Sotorasib", "type": "DRUG" }, { "name": "Trametinib", "type": "DRUG" }, { "name": "RMC-4630", "type": "DRUG" }, { "name": "Afatinib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Panitumumab", "type": "DRUG" }, { "name": "Carboplatin, pemetrexed, docetaxel, paclitaxel", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "MVASI® (bevacizumab-awwb)", "type": "DRUG" }, { "name": "TNO155", "type": "DRUG" }, { "name": "IV Chemotherapy (Regimen 1)", "type": "DRUG" }, { "name": "IV Chemotherapy (Regimen 2)", "type": "DRUG" }, { "name": "BI 1701963", "type": "DRUG" }, { "name": "AMG 404", "type": "DRUG" }, { "name": "Everolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 610, "start_date": "2019-12-17", "completion_date": "2027-12-05", "has_results": false, "last_update_posted_date": "2025-10-22", "last_synced_at": "2026-10-02T05:57:50.521Z", "location_count": 55, "location_summary": "Tucson, Arizona • Duarte, California • La Jolla, California + 42 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Loma Linda", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04185883" }, { "nct_id": "NCT02578732", "title": "FOLFOX-A For Locally Advanced Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Locally Advanced Pancreatic Cancer", "Pancreatic Cancer" ], "interventions": [ { "name": "FOLFOXA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Brown University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2016-07-12", "completion_date": "2022-03-16", "has_results": true, "last_update_posted_date": "2023-05-06", "last_synced_at": "2026-10-02T05:57:50.521Z", "location_count": 1, "location_summary": "Providence, Rhode Island", "locations": [ { "city": "Providence", "state": "Rhode Island" } ], "official_url": "https://clinicaltrials.gov/study/NCT02578732" }, { "nct_id": "NCT05067283", "title": "A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "Calderasib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "pemetrexed", "type": "DRUG" }, { "name": "cetuximab", "type": "BIOLOGICAL" }, { "name": "oxaliplatin", "type": "DRUG" }, { "name": "leucovorin", "type": "DRUG" }, { "name": "5-fluorouracil", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 830, "start_date": "2021-12-17", "completion_date": "2030-02-25", "has_results": false, "last_update_posted_date": "2026-09-14", "last_synced_at": "2026-10-02T05:57:50.521Z", "location_count": 6, "location_summary": "Tampa, Florida • Grand Rapids, Michigan • Hackensack, New Jersey + 3 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "New York", "state": "New York" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05067283" } ] }